Although furtherclinical data are expected, these findings were shown to be promisingas a new opportunity for the treatment of T2DM patients, in additionto the combinations of SGLT-2 inhibitors and DPP-4 inhibitors (saxagliptin-dapagliflozinand linagliptin-empagliflozin) already approved for T2DM treatment.125,130,133. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.